Prospective Double-Blinded Randomized Field-Based Clinical Trial of Metoclopramide and Ibuprofen for the Treatment of High Altitude Headache and Acute Mountain Sickness
| Autor: | Renee N Salas, Salman Bhai, N. Stuart Harris, W. Douglas Gregorie, Hillary R. Irons |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Metoclopramide Nausea Visual analogue scale Ibuprofen Altitude Sickness Young Adult 03 medical and health sciences 0302 clinical medicine Double-Blind Method Nepal medicine Humans Cyclooxygenase Inhibitors Prospective Studies business.industry organic chemicals Anti-Inflammatory Agents Non-Steroidal Headache Public Health Environmental and Occupational Health 030208 emergency & critical care medicine 030229 sport sciences Middle Aged Effects of high altitude on humans medicine.disease Mountaineering Clinical trial Dopamine D2 Receptor Antagonists Treatment Outcome Migraine Anesthesia Emergency Medicine Antiemetics Female medicine.symptom Headaches business medicine.drug |
| Zdroj: | Wilderness & Environmental Medicine. 31:38-43 |
| ISSN: | 1080-6032 |
| DOI: | 10.1016/j.wem.2019.11.005 |
| Popis: | Introduction High altitude headache (HAH) and acute mountain sickness (AMS) are common pathologies at high altitudes. There are similarities between AMS and migraine headaches, with nausea being a common symptom. Several studies have shown ibuprofen can be effective for AMS prophylaxis, but few have addressed treatment. Metoclopramide is commonly administered for migraine headaches but has not been evaluated for HAH or AMS. We aimed to evaluate metoclopramide and ibuprofen for treatment of HAH and AMS. Methods We performed a prospective, double-blinded, randomized, field-based clinical trial of metoclopramide and ibuprofen for the treatment of HAH and AMS in 47 adult subjects in the Mount Everest region of Nepal. Subjects received either 400 mg ibuprofen or 10 mg metoclopramide in a 1-time dose. Lake Louise Score (LLS) and visual analog scale of symptoms were measured before and at 30, 60, and 120 min after treatment. Results Subjects in both the metoclopramide and ibuprofen arms reported reduced headache severity and nausea compared to pretreatment values at 120 min. The ibuprofen group reported 22 mm reduction in headache and 6 mm reduction in nausea on a 100 mm visual analog scale at 120 min. The metoclopramide group reported 23 mm reduction in headache and 14 mm reduction in nausea. The ibuprofen group reported an average 3.5-point decrease on LLS, whereas the metoclopramide group reported an average 2.0-point decrease on LLS at 120 min. Conclusions Metoclopramide and ibuprofen may be effective alternative treatment options in HAH and AMS, especially for those patients who additionally report nausea. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect